Table 2.
Time Post- HAART |
No. samples |
Viral Failure (95% CI) |
No. pools |
No. individual assays performed |
Total no. assays performed |
No. assays saved |
Relative Efficiency (%) (95% CI) |
Cost savings (per 100 assays saved) |
---|---|---|---|---|---|---|---|---|
Overall | 250 | 13.6 (9.6–18.5) | 50 | 141 | 191 | 59 | 23.6 (18.5–29.4) | $1,180 |
6 month | 49* | 12.2 | 10 | 22 | 32 | 17 | 35 (22–50) | $1,735 |
1–2 years | 50 | 12.0 | 10 | 25 | 35 | 15 | 30 (18–45) | $1,500 |
2–3 years | 50 | 16.0 | 10 | 40 | 50 | 0 | 0 (0–7) | $0 |
3–4 years | 50 | 14.0 | 10 | 29 | 39 | 11 | 22 (12–36) | $1,100 |
4–5 years | 50 | 14.0 | 10 | 24 | 34 | 15 | 30 (18–45) | $1,500 |
A total of 250 archived plasma samples were obtained for ART monitoring and pooled in groups of 5 samples according to time post-ART for detection of virologic failure.
After compilation and testing of pools, one sample was found to be out of the desired range and is excluded from the 6 month time interval.